Extra Space Storage, Inc. vs Sana Biotechnology Inc — how do they compare? Extra Space Storage, Inc. trades at $147.98 (market cap $30.56B), while Sana Biotechnology Inc trades at $3.41 (market cap $987.94M). The key difference: Extra Space Storage, Inc. is far larger — about 30.9× Sana Biotechnology Inc's market cap, and Extra Space Storage, Inc. pays a 4.48% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| EXR | SANA | |
|---|---|---|
Market Cap | $30.56B | $987.94M |
Sector | Real Estate | Health |
52-Week High | $152.75 | $5.92 |
52-Week Low | $126.67 | $2.68 |
Enterprise Value | $44.36B | $962.13M |
Dividend Yield | 4.48% | — |
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $145.50, showing modest daily gains of 0.12%. The stock exhibits neutral technical signals with support around $145 and resistance near $146. Fundamentally, the company maintains strong profitability with a 70.63% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights steady expansion and a new $550 million debt issuance at favorable rates, while analyst coverage shows a mixed consensus leaning toward Hold positions.
The outlook for EXR balances steady operational performance against valuation concerns. Investment opportunities include resilient self-storage demand, consistent dividend payments ($1.62 quarterly), and strategic acquisitions. Key risks involve elevated debt levels, new market supply pressures, and expense growth outpacing revenue. With a consensus price target of $155.88 suggesting 7% upside, the stock presents moderate growth potential tempered by sector headwinds.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Trailing returns across standard periods
Latest headlines on both assets
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →